Tag: BioNTech
Syncona’s Autolus and BioNTech forge alliance to propel CAR-T therapies
Syncona Ltd, a prominent investor in the life sciences sector, has announced a significant strategic collaboration through its portfolio company, Autolus Therapeutics plc, with BioNTech ... Read More
BioNTech to buy UK-based tech firm InstaDeep for AI-powered drug discovery
German biotechnology company BioNTech has agreed to acquire 100% of the remaining InstaDeep shares for an upfront consideration of around £362 million in cash and ... Read More
FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five
Pfizer and BioNTech have received the US Food and Drug Administration (FDA) emergency use authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine for children ... Read More
BioNTech to launch construction of mRNA-based vaccine facility in Africa
BioNTech revealed plans to launch the construction of a manufacturing plant for mRNA-based vaccines in the African Union mid-next year. The German biotech company said ... Read More
Pfizer withdraws application for BNT162b2 Covid-19 vaccine in India
US pharma giant Pfizer has withdrawn its application in India seeking emergency use authorization for its BNT162b2 Covid-19 vaccine. The decision to withdraw the coronavirus ... Read More
Swissmedic authorizes use of BNT162b2 Covid-19 vaccine from Pfizer, BioNTech
Swissmedic, the Swiss Agency for Therapeutic Products, has authorized the use of the BNT162b2 Covid-19 vaccine from US pharma giant Pfizer and German biotech company ... Read More
Pfizer and BioNTech secure FDA EUA for BNT162b2 Covid-19 vaccine
BNT162b2 FDA EUA : Pfizer and BioNTech have been granted emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for BNT162b2, their ... Read More
Pfizer, BioNTech get Canadian approval for BNT162b2 Covid-19 vaccine
US pharma giant Pfizer and German biotech company BioNTech have bagged Health Canada approval for their BNT162b2 Covid-19 vaccine. The BNT162b2 vaccine has been authorized ... Read More
UK authorizes Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine
The UK has given a temporary authorization for emergency use for the BNT162b2 Covid-19 vaccine candidate developed by Pfizer and BioNTech. The emergency use authorization ... Read More
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech
Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in ... Read More